Running title: Glargine initiation in insulin-naïve type 2 diabetes AT.LANTUS: A Trial comparing LANTUS Algorithms to achieve Normal blood glucose Targets in subjects with Uncontrolled blood Sugar 2 ABSTRACT Objective: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide optimal glycemic control, necessitating insulin therapy. Fear of hypoglycemia is a major barrier to initiating insulin therapy. The AT.LANTUS study investigated optimal methods to initiate and maintain insulin glargine (LANTUS ® ; glargine) therapy using two treatment algorithms. This sub-group analysis investigated the initiation of once-daily glargine therapy in patients sub-optimally controlled on multiple OADs.
Achieving and maintaining tight glycemic control for patients with type 2 diabetes is essential to delay progression of micro-and macrovascular complications [1] . Targets for HbA 1c have been set as <7.0%, 6.5-7.5% and <6.5% by the American Diabetes Association [2] , National
Institute for Health and Clinical Excellence in the UK [3] and the International Diabetes Federation [4] , respectively. However, the majority of patients with type 2 diabetes are unable to reach target HbA 1c levels [5, 6] .
Following diagnosis, patients are generally advised to make a number of lifestyle changes, focussed on increasing physical activity levels [7] and diet [8] . However, such programs are usually insufficient by this stage of the diabetes [9] . The progressive nature of T2DM, characterized by a decline in β-cell function [10, 11] and deterioration in glycemic control [12] , means that pharmacologic interventions are usually required [13] . Oral antidiabetic agents (OADs), for example, sulfonylureas, metformin and glitazones are therapeutic interventions used in monotherapy or in combination. However, to achieve and maintain good glycemic control, OADs, even in combination, are insufficient [14] and insulin therapy is often required [13] .
Both patients and physicians may be reluctant to start insulin therapy [6, 15, 16] . The fear of hypoglycemia, needle anxiety and weight gain are among the reasons cited that actively discourage insulin therapy. Therefore, it is important that for insulin therapy to be effective in patients with type 2 diabetes, these barriers must be overcome.
Insulin glargine (LANTUS ® , glargine) is the first clinically available basal analog with no pronounced peak in activity and a 24-hour duration of action following once-daily administration [17] . In type 2 diabetes, insulin glargine has at least equivalent glycemic control [18] [19] [20] with a lower incidence of hypoglycemia compared with NPH insulin [20] [21] [22] [23] [24] [25] .
Therefore, insulin glargine could potentially be used as part of a more intensive treatment regimen to achieve target HbA 1c levels ≤7% with a lower risk of hypoglycemia. Combination 4 therapy of insulin glargine in conjunction with one or more OADs is an effective and simple regimen in patients with type 2 diabetes who have sub-optimal control on OADs alone [26, 27] .
Whilst little is known regarding the optimal titration regimen for initiating basal insulin therapy, the Treat-to-Target study [25] demonstrated that aggressive titration, in the context of an intensive and fully resourced clinical trial setting, can result in ~60% of patients achieving target HbA 1c of ≤7%.
We recently showed that two treatment algorithms, one largely clinic-driven and the other primarily patient-driven, can be introduced to a large cohort of subjects [28] . Given the largescale nature of the AT.LANTUS study (59 countries, 4961 patients) and the diversity of prior treatment, it has been possible to perform a number of post hoc sub-analyses on different sub-populations. One of the most likely clinical contexts in which basal insulin is initiated in type 2 diabetes is in those with sub-optimal glycaemic control on OADs; thus, results in this particular sub-group are of particular relevance. Here we report the findings of a sub-group analysis of insulin-naïve patients sub-optimally controlled with OADs who took part in the AT.LANTUS study.
RESEARCH DESIGN AND METHODS

Study design
This was a prospective, multinational (611 centers in 59 countries in Western and Eastern Europe, South America, Asia and Africa/Middle East), randomized controlled, parallel-design study of 24 weeks duration of 4961 type 2 diabetes patients. This study included only four mandatory clinical visits, similar to standard clinical practice. All patients gave informed consent in accordance with the Declaration of Helsinki and the study was performed in accordance with Good Clinical Practice. Full details are available elsewhere [28] .
Inclusion criteria for the total population [28] included: subjects aged ≥18 years on antidiabetic treatment (any oral and/or insulin therapy) for >6 months; HbA 1c levels >7.0% and <12.0%; body mass index (BMI) values <40 kg/m 2 and a willingness to perform selfmonitored blood glucose. Additional sub-group analysis criteria included insulin-naïve patients sub-optimally controlled with >1 OAD. Exclusion criteria were in accordance with the manufacturer's prescribing information.
In this paper we discuss the sub-group analysis of subjects who were previously taking only OADs. At baseline, subjects were randomized (1:1) to receive insulin glargine according to Algorithm 1 (clinic-driven titration) or Algorithm 2 (patient-driven titration) ( Table 1) .
[ Table 1 near here]
At baseline, the investigator decided whether to continue each OAD, in line with the prescribing information. Once it was decided whether the subject should take one or >1
OAD, the dose of OAD(s) remained fixed and stable for the duration of the study. As thiazolidinediones were not licensed for use in combination with insulin at the time this study was conducted, for any patients using a thiazolidinedione during screening, the investigators were asked to switch therapy, in line with the prescribing information.
Objectives
The primary objective of the full study was to compare the two treatment algorithms for the initiation and maintenance of insulin glargine based on the incidence of severe hypoglycemia, defined according to criteria used in the Diabetes Control and Complications
Trial (DCCT) [29, 30] .
The primary outcome measure for this sub-group analysis was the comparison between algorithms for the incidence of severe, symptomatic and nocturnal hypoglycemia. Secondary outcomes included glycemic control (HbA 1c and fasting blood glucose [FBG] ) and change in insulin dose from baseline. The study endpoint was defined by the subject's last observation (Visit 12 for those completing the study, or last clinic for those missing data on Visit 12). If a subject discontinued treatment permanently before the planned study end, the last evaluation before discontinuation was considered for the endpoint analysis.
Measurements and safety
At screening, biochemistry and hematology measurements were taken. HbA 1c and weight were measured at screening, baseline and Weeks 12 and 24. Analyses of HbA 1c were performed by the laboratory of each participating site, either according to the DCCT standard method or a DCCT-aligned method within a documented quality controlled system. FBG levels on 6 consecutive days before and on the day of a visit were measured by subjects weekly from baseline to Week 24. Glucose monitors were provided for self-monitored blood glucose. The glucose meters used a standardized platform for the entire study and reported results in whole blood. Data and calibration of blood glucose meters was verified at clinical visits.
Safety assessments in each treatment algorithm included adverse event (AE) reporting, excluding the primary and secondary outcomes. All AEs, including non-treatment emergent
AEs were recorded.
Statistical methods
The statistical and reporting methods used in this sub-analysis were similar to those used in the main AT.LANTUS study [28] . In the full study population, the primary efficacy variable (frequency of severe hypoglycemia) was evaluated using a two-sided 90% confidence interval (CI) with equivalence declared if the 90% CI was contained in the pre-defined equivalence boundaries (-1.5; 1.5%). For analyses presented here, patients treated at baseline with more than one OAD were isolated and a descriptive analysis produced.
Analyses were performed for two subgroups defined according to the number of OADs received at randomization (one or more than one OAD), and who remained on the same treatment regimen throughout the study. All analyses presented here were performed on an exploratory basis. The analyses were undertaken on non-randomized sub-groups of patients without adjustment for multiple testing, and were based on the per-protocol population.
Changes from baseline in HbA 1c , FBG, body weight and insulin dose were analysed using analysis of covariance. Student's t-test and the chi-square test were also used as appropriate. A p-value <0.05 was considered statistically significant. Statistical analyses were performed using SAS version 8 (SAS Inc, Cary, NC). completed the study to form the per-protocol population; reasons for discontinuation, Algorithm 1 versus Algorithm 2, were patient not followed to final visit (5 vs 7 subjects) and major protocol violations (8 vs 6 subjects).
RESULTS
Results of independent audits performed in accordance with
Subject demographics and baseline characteristics were broadly similar between the two treatment groups and within each algorithm, although patients in the >1 OAD treatment group tended to have a longer duration of OAD treatment compared with patients in the 1 OAD treatment group (Table 2) .
[ Table 2 near here]
While data presented are based on the per-protocol analysis, full intention-to-treat analyses were performed. The results were virtually identical and, therefore, did not differ clinically or statistically and are not presented here.
Hypoglycemia
The incidence of severe, symptomatic and nocturnal hypoglycemia in patients receiving insulin glargine via either treatment algorithm plus either 1 OAD or >1 OAD is summarised in Table 3 . The incidence of severe hypoglycemia was <1% in both treatment groups, with no significant difference between the treatment algorithms.
[ Table 3 near here]
HbA 1c
In subjects receiving insulin glargine plus 1 OAD, there was a significant baseline to endpoint decrease in HbA 1c in both algorithms ( Figure 1A ). Algorithm 2 was associated with a greater reduction compared with Algorithm 1 (-1.5 vs -1.3%; p=0.03). Significant reductions in HbA 1c from baseline to endpoint were also observed in patients receiving insulin glargine plus >1 OAD in both algorithms ( Figure 1A ). Algorithm 2 was associated with a greater reduction compared with Algorithm 1 (-1.8 vs -1.5%; p=0.001).
At endpoint, in subjects receiving insulin glargine plus 1 OAD, 24% had reached target
HbA 1c levels ≤7% with Algorithm 1 compared with 38% of subjects with Algorithm 2 (p=0.009) and in subjects receiving insulin glargine plus >1 OAD, 31% had reached target
HbA 1c levels ≤7% with Algorithm 1 compared with 43% of subjects with Algorithm 2 (p=0.007). Significantly more subjects achieved HbA 1c levels ≤7% without experiencing either severe or nocturnal hypoglycemia in Algorithm 2 versus Algorithm 1 in subjects receiving both insulin glargine plus 1 OAD (33 vs 21%; p=0.02) and insulin glargine plus >1 OAD (37 vs 28%; p=0.03).
[Figure 1 near here]
Fasting blood glucose FBG decreased significantly from baseline to endpoint in all sub-groups (p<0.001; Figure   1B ), but the reduction in FBG was significantly greater for subjects randomized to Algorithm 
Insulin glargine dose
For patients receiving 1 OAD, the increases in insulin dose were significantly greater for patients randomized to Algorithm 2 (+33.9 U; range: -8 to +128 U [+0.39 U/kg]) compared with Algorithm 1 (+27.4 U, p=0.04; range: -2 to +104 U [+0.32 U/kg, p=0.03]; Figure 1C ). For patients receiving >1 OAD, the increases in insulin dose were not significantly different in the patients randomized to Algorithm 1 (+19.9 U; range: -6 to +100 U [+0.23 U/kg]) or Algorithm 2 (+22.8 U, p=0.57; range: -16 to +114 U [+0.27 U/kg, p=0.20]; Figure 1C ).
Body weight
In subjects receiving both 1 OAD and >1 OAD, there was a modest statistically significant (p<0.001) increase in body weight from baseline to endpoint with both Algorithm 1 
Safety
In the main study, treatment-emergent adverse events were reported in 48.7% of patients; their overall frequency was similar between the algorithms [28] . In this sub-group analysis, the incidence of adverse events was similar to that of the main study (data not shown).
CONCLUSIONS
The AT.LANTUS study is one of the largest randomized clinical studies (n=4961 patients) of glycemic management performed in subjects with type 2 diabetes, and the results will be applicable to many patients in a clinical setting [28] . This sub-group analysis, undertaken in 865 subjects, included all insulin-naïve patients who were previously sub-optimally controlled on multiple OADs. The results presented here demonstrate that two simple insulin initiation and treatment algorithms were highly effective in safely achieving and maintaining glycemic control. Furthermore, these results were achieved regardless of concomitant OAD therapy (+1 OAD or >1 OAD) along with a very low incidence of severe hypoglycemia.
We have previously published results from the overall population; changes in HbA 1c were - 1.5% for patients previously on twice-daily premixed insulin plus OADs [32] .
The fears of weight gain and hypoglycemia are significant barriers to the initiation of insulin therapy in type 2 diabetes [15, 33] . In this sub-group analysis, weight gain was relatively modest (range: 1.4-2.1 kg over 24 weeks) in the context of significant improvement in glycemic control with 24-43% of patients reaching target HbA 1c levels of ≤7.0%. This occurred with a comparatively low incidence of severe hypoglycemia. Furthermore, these benefits were seen regardless of concomitant OAD therapy. Therefore, therapy with basal insulin glargine plus OADs may provide the impetus to overcome the fears of hypoglycemia and weight gain.
In our study, no patients in the insulin glargine +1 OAD group experienced severe hypoglycemia and <1% of the patients in the >1 OAD group experienced severe hypoglycemia, which compares favorably with that reported by the UK Prospective Diabetes Study (UKPDS; 2.3% for patients treated with insulin) [34] . Furthermore, our study was of patients with long-standing type 2 diabetes, with a mean duration since diagnosis of 10 years and mean duration of OAD therapy of >7 years, whereas the UKPDS included only newly diagnosed (insulin and OAD naïve) patients.
In 35, 36] . A further reason for the lower proportion of patients reaching HbA 1c <7% is that we did not force the titration of insulin glargine, whereas the Treat-to-Target study did. As a result, the rates of hypoglycemia were lower in our study. This suggests that titration of insulin glargine dose could be more aggressive, to better reach treatment targets, although this must be balanced against the inevitable risk of hypoglycemia.
While a shortcoming of the current study may be the lack of a placebo arm, the reduction in HbA 1c (>1%) observed in this study is greater than might be expected as a result of a placebo effect. A further shortcoming of the present study, is that it was conducted as an exploratory analysis of a large sub-group (n=865) of patients from the original AT.LANTUS study (n=4961 patients). As such, the analyses were mainly descriptive. However, as a large proportion of patients from the original study were included in the analyses presented here and that the analysis includes a similar number of patients used in trials such as the Treat to Target study [25] , one would expect that the results show a high degree of statistical power and support the need for confirmatory studies.
Whilst additional prospective randomized studies may be necessary to further confirm the results reported, it is evident that the current sub-analysis confirms the results of the Treat to 14 Target study. The distinguishing feature here is that patient-driven titration appears to achieve greater HbA 1c benefits with more patients reaching target HbA 1c at endpoint, twice the percentage of patients reaching target FBG (72% vs 36%) and a lower incidence of severe hypoglycemia, all in the absence of the use of thiazolidinediones.
Physicians currently face a number of options for transferring patients from combination OAD therapy to insulin, including multiple daily or basal injections and whether to continue or change OAD therapy. In a recent meta-analysis [38] of four trials comparing insulin glargine with NPH insulin in patients with type 2 diabetes [22, 24, 25, 39] , insulin glargine was associated with significantly lower incidence of hypoglycemia in conjunction with improved HbA 1c and this occurred despite similar increases in dose from baseline to endpoint (20-28 weeks) from 21 to 38 U for insulin glargine and 21 to 37 U for NPH insulin. The relative merits of twice-daily premixed insulin versus once-daily basal insulin are often debated. One study has shown that once-daily insulin glargine plus metformin was more effective at lowering HbA 1c than a twice-daily premixed insulin regimen, but a criticism was that metformin was discontinued in the premixed insulin arm, and a conventional premixed insulin was used [40] . In comparison, in two studies, where OADs were continued and comparing biphasic analog mixtures (Lispro Mix 75/25 or Aspart Mix 70/30) with insulin glargine, the premixed insulin regimens were associated with greater reductions in HbA 1c [35, 41] . However, the premixed insulin regimens were also associated with significantly higher incidence of hypoglycemia and greater weight gain compared with insulin glargine.
In the LANMET study [21] , which investigated the addition of either insulin glargine or NPH insulin to metformin therapy, the percentage of patients in the insulin glargine group experiencing hypoglycemia were 46 and 43% during Weeks 0-12 and 13-24, respectively.
By comparison, a smaller proportion of patients experienced symptomatic hypoglycemia in our study (<19%). This may be due to the titration methods used in the two studies, insulin doses reached ~60 U by Week 24 in the LANMET study, whereas in our study, the mean insulin dose was <46 U for all sub-analysis groups. This balance between high insulin dose, change in HbA 1c and risk of hypoglycaemia is trade-off that will need to be acceptable for the patient. In our study, we used algorithm based on avoidance of hypoglycaemia with allowances for decreasing insulin dose in the event of regular hypoglycaemia, thus limiting the extent to which insulin doses can be increased.
In a study investigating continued sulfonylurea and metformin with either insulin glargine or rosiglitazone (patients previously treated with sulfonylurea and metformin), insulin glargine was associated with significantly improved glycemic control (HbA 1c and FBG) [27] . While the incidence of hypoglycemia was higher in the insulin glargine group, less weight gain and fewer adverse events occurred in the insulin glargine group.
In studies with insulin glargine [25, 27, 40, 41] , the starting dose of insulin glargine was typically 10-20 U. By endpoint (20-28 weeks), the dose had increased to 25-40 U. In our study, patients in both treatment algorithms with >1 OAD achieved similar doses at Week 24. However, those patients on 1 OAD achieved a greater increase in basal insulin dose when encouraged to self-titrate.
Effective and efficient use of scarce healthcare resources is an important aspect of care. An approach which increases patient-driven management is as effective and reduces the need for face to face contact with healthcare professionals is thus potentially a more effective use of healthcare resources. However, it has been reported that healthcare providers underestimate the proportion of patients who would be willing to take part in decision-making about their treatment [42] .
The approach to insulin initiation and dose titration with a single injection of insulin titrated against a fasting blood glucose level [37] , as used here, is a simple and consistent approach, which is conducive to being taught in a group setting, and has also been shown to be a more effective use of healthcare professional time. Indeed, in a study by Yki-Jarvinen et al, were patients were encouraged to self-adjust their insulin dose, with education delivered either in a group or individual setting, improvements in HbA 1c were similar in both arms The findings presented here support those observed in the full cohort, that two simple, widely applicable titration algorithms (either patient-or physician-driven) for the initiation of glargine can be implemented in clinical practice with low incidence of hypoglycemia. We also
show that patient-driven dose titration achieves more pronounced improvements in glycemic control compared with physician-driven titration, and this improvement is not associated with an increased risk of hypoglycemic episodes. Moreover, subjects with type 2 diabetes, sub- Magnitude of daily basal dose was at the discretion of the investigator. Diabetes duration (years) 9.3 ± 5.5 9.7 ± 6.5 10.4 ± 5.7 10.5 ± 6.6
FBG=fasting blood glucose
Duration of OAD therapy (years) 7.9 ± 5.7 7.7 ± 5.8 9.2 ± 5.1 9.4 ± 6.2
HbA 1c (%) 9.1 ± 1.3 9.1 ± 1.3 9.1 ± 1. 
